At 55.4% CAGR Transthyretin Amyloidosis Treatment Market To Reach US$ 1,218.3 Million By 2026
Global , by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is expected to be valued at US$ 35.8 million in 2018 and is estimated to exhibit a CAGR of 55.4% over the forecast period (2018-2026), as highlighted in a new report p...